Increased risk of mycotic infections associated with sodium–glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis

British Journal of Clinical Pharmacology

Volumn 85, Issue 1, 2019, Pages 160-168

  Adimadhyam, Sruthi ^a   Schumock, Glen T ^a   Calip, Gregory S ^a,b   Smith Marsh, Daphne E ^a   Layden, Brian T ^a,c   Lee, Todd A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Jesse Brown Veterans Affairs Medical Center   (United States)

Author keywords

diabetes; drug safety; evidence based medicine; pharmacoepidemiology

Indexed keywords

ANTIFUNGAL AGENT; BUTOCONAZOLE; CANAGLIFLOZIN; CLOTRIMAZOLE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFANILAMIDE; TERCONAZOLE; TIOCONAZOLE;

ADULT; ANTIFUNGAL THERAPY; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYCOSIS; PRESCRIPTION; PRIORITY JOURNAL; ADMINISTRATION AND DOSAGE; ADVERSE EVENT; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK FACTOR; SEX FACTOR;

ANTIFUNGAL AGENTS; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOSES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85056156884     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13782     Document Type: Article

References (34)

1. Triplitt CL, Repas T, Alvarez C. Chapter 57. Diabetes mellitus. In: Pharmacotherapy: A Pathophysiologic Approach, 9e, eds DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. New York, NY: The McGraw-Hill Companies, 2014. Available at accesspharmacy.mhmedical.com/content.aspx?aid=57496051 (last accessed 19 June 2017).
2. Association AD. 2. Classification and diagnosis of diabetes. Diabetes Care 2017; 40 (Suppl. 1): S11–S24. https://doi.org/10.2337/dc17-S005.
3. Fowler MJ. Diagnosis, classification, and lifestyle treatment of diabetes. Clin Diabetes 2010; 28: 79–86.
4. American Diabetes Association. Fast Facts - Data and Statistics About Diabetes|American Diabetes Association. Available at http://professional.diabetes.org/content/fast-facts-data-and-statistics-about-diabetes (last accessed 3 May 2017).
5. World Health Organization. Global Report on Diabetes. Geneva: World Health Organization, 2016.
6. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262–274.
7. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.
8. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
9. ® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2015. Available at https://www.invokanahcp.com/dosing-prescribing (last accessed 17 July 2017).
10. FARXIGA [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2016. Available at https://www.farxiga-hcp.com/ (last accessed 17 July 2017).
11. JARDIANCE [prescribing information]. Ridgefort, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2015. Available at https://jardiancehcp.com/ (last accessed 17 July 2017).
12. Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 2018; 55: 503–514.
13. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 457–466.
14. Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 2016; 11: e0166125.
15. Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 2017; 19: 348–355.
16. Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care 2017; 40: 1425–1432.
17. Lai ECC, Pratt N, Hsieh CY, Lin SJ, Pottegård A, Roughead EE, et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol 2017; 32: 567–582.
18. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996; 7: 478–484.
19. Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf 2009; 18: 483–491.
20. Pratt NL, Ilomäki J, Raymond C, Roughead EE. The performance of sequence symmetry analysis as a tool for post-market surveillance of newly marketed medicines: a simulation study. BMC Med Res Methodol 2014; 14: 66.
21. Chang S. Health Research Data for the Real World: the MarketScan Databases. 2011. Available at http://truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf (last accessed 19 September 2017).
22. van Boven JFM, de Jong-van den Berg LT, Vegter S. Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis. Drug Saf 2013; 36: 231–236.
23. Morris JA, Gardner MJ. Statistics in medicine: calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J Clin Res Ed 1988; 296: 1313–1316.
24. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016; 18: 783–794.
25. Wu JHY, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4: 411–419.
26. Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014; 30: 1109–1119.
27. Huilin Tang M, Jingjing Zhang MD, Yiqing Song MD. Adverse effects and safety of SGLT2 inhibitor use among patients with type 2 diabetes: findings from RCT evidence. North Am J Med Sci 2017; 10: 78–82.
28. US Food and Drug Administration. Drug Safety and Availability - FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate. Available at https://www.fda.gov/Drugs/DrugSafety/ucm500965.htm (last accessed 16 March 2018).
29. US Food and Drug Administration. Safety Alerts for Human Medical Products - Invokana and Invokamet (canagliflozin): Drug Safety Communication - New Information on Bone Fracture Risk and Decreased Bone Mineral Density. Available at http://wayback.archive-it.org/7993/20170112164004/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm461876.htm (last accessed 15 August 2017).
30. Gadzhanova S, Pratt N, Roughead E. Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Res Clin Pract 2017; 130: 180–185.
31. Gurwitz JH, McLaughlin TJ, Fish LS. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products. Health Serv Res 1995; 30: 672–685.
32. Pouwels KB, Visser ST, Bos HJ, Hak E. Angiotensin-converting enzyme inhibitor treatment and the development of urinary tract infections: a prescription sequence symmetry analysis. Drug Saf 2013; 36: 1079–1086.
33. Wahab IA, Pratt NL, Wiese MD, Kalisch LM, Roughead EE. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol Drug Saf 2013; 22: 496–502.
34. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med 2013; 125: 33–46.